Related references
Note: Only part of the references are listed.Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T
Abhishek A. Mangaonkar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts, thrombocytosis, and mutated JAK2/SF3B1 without anemia
Neil Montgomery Neumann et al.
BLOOD (2022)
SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
Abhishek A. Mangaonkar et al.
HAEMATOLOGICA (2022)
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
Abhishek A. Mangaonkar et al.
BLOOD CANCER JOURNAL (2022)
Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) andSF3B1
Chi Young Ok et al.
MODERN PATHOLOGY (2021)
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts
Felicitas Schulz et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial
Emanuele Angelucci et al.
ANNALS OF INTERNAL MEDICINE (2020)
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
Bianca Rocca et al.
BLOOD (2020)
Thrombosis among 1537 patients with JAK2V617F-mutated myeloproliferative neoplasms: Risk factors and development of a predictive model
Yuhui Zhang et al.
CANCER MEDICINE (2020)
Thrombocytosis and Thrombosis: Is There Really a Correlation?
Carlos Galvez et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
M. D. Cappellini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding
Hassan Awada et al.
CANCERS (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia
Jonathan Feld et al.
LEUKEMIA RESEARCH (2020)
Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series
Maria Tariq Siddiqui et al.
BLOOD (2020)
Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)
Guillermo Montalban Bravo et al.
BLOOD (2020)
Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study
Rami S. Komrokji et al.
BLOOD (2020)
Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review
Lucas Affentranger et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Abdulraheem Yacoub et al.
BLOOD (2019)
Somatic SF3B1 mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia
Allister Foy et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
Guadalupe Belen Antelo et al.
BLOOD (2019)
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
Michael R. Savona et al.
BLOOD (2019)
Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms
Leonardo Boiocchi et al.
HUMAN PATHOLOGY (2019)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux et al.
LEUKEMIA (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Shannon A. Wong et al.
LEUKEMIA RESEARCH (2018)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis
Megan Melody et al.
BLOOD (2018)
Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
Kiran Naqvi et al.
BLOOD (2018)
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
M. Robin et al.
BONE MARROW TRANSPLANTATION (2017)
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
U. Platzbecker et al.
LEUKEMIA (2017)
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Claire N. Harrison et al.
BLOOD (2017)
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Elias Jabbour et al.
BLOOD (2017)
Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia A Systematic Review
Derek K. Chu et al.
ANNALS OF INTERNAL MEDICINE (2017)
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
A. Toma et al.
LEUKEMIA (2016)
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis
M. M. Patnaik et al.
LEUKEMIA (2016)
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
A. Tefferi et al.
BLOOD CANCER JOURNAL (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations
Ryan Keen et al.
HEMATOLOGY REPORTS (2016)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona et al.
BLOOD (2015)
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera
Marina Kremyanskaya et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations
Sabine Jeromin et al.
HAEMATOLOGICA (2015)
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms
Mario Cazzola et al.
BLOOD (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
J. Broseus et al.
LEUKEMIA (2013)
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mhairi Mitchell et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
Julien Broseus et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis A Mixed Group Exhibiting a Spectrum of Morphologic Findings
Inga Gurevich et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
Ring sideroblasts and sideroblastic anemias
Mario Cazzola et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease
Suetonia C. Palmer et al.
ANNALS OF INTERNAL MEDICINE (2010)
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis
Gerwin Huls et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Luca Malcovati et al.
BLOOD (2009)
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
Alessandra Carobbio et al.
EXPERIMENTAL HEMATOLOGY (2009)
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features
A. Orazi et al.
LEUKEMIA (2008)
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Annette H. Schmitt-Graeff et al.
HAEMATOLOGICA (2007)
High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis
A. Renneville et al.
LEUKEMIA (2006)
The JAK2 V617F mutation is rare in RARS but common in RARS-T
M. M. Ceesay et al.
LEUKEMIA (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
Hadrian Szpurka et al.
BLOOD (2006)
The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)
Marjorie Boissinot et al.
BLOOD (2006)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia
A Tomer
BLOOD (2002)
Share Paper
